ID   LRRK2_HUMAN             Reviewed;        2527 AA.
AC   Q5S007; A6NJU2; Q6ZS50; Q8NCX9;
DT   24-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   20-APR-2010, sequence version 2.
DT   02-NOV-2010, entry version 71.
DE   RecName: Full=Leucine-rich repeat serine/threonine-protein kinase 2;
DE            EC=2.7.11.1;
DE   AltName: Full=Dardarin;
GN   Name=LRRK2; Synonyms=PARK8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANTS PARK8
RP   VAL-1122; CYS-1441; CYS-1699 AND THR-2020.
RC   TISSUE=Brain;
RX   PubMed=15541309; DOI=10.1016/j.neuron.2004.11.005;
RA   Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M.,
RA   Lincoln S.J., Kachergus J.M., Hulihan M.M., Uitti R.J., Calne D.B.,
RA   Stoessl A.J., Pfeiffer R.F., Patenge N., Carballo Carbajal I.,
RA   Vieregge P., Asmus F., Mueller-Myhsok B., Dickson D.W., Meitinger T.,
RA   Strom T.M., Wszolek Z.K., Gasser T.;
RT   "Mutations in a large multifunctional protein (LRRK2) cause autosomal
RT   dominant parkinsonism with pleiomorphic a-synuclein and tau-pathology
RT   (PARK8).";
RL   Neuron 44:601-607(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2128-2527.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   DISEASE.
RX   PubMed=16081470; DOI=10.1093/brain/awh607;
RA   Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J.,
RA   Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T.,
RA   Uitti R.J., Calne D.B., Wszolek Z.K., Stoessl A.J.;
RT   "PET in LRRK2 mutations: comparison to sporadic Parkinson's disease
RT   and evidence for presymptomatic compensation.";
RL   Brain 128:2777-2785(2005).
RN   [5]
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANT PARK8 THR-2020.
RX   PubMed=16321986; DOI=10.1093/hmg/ddi439;
RA   Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E.,
RA   Meitinger T., Kolch W., Prokisch H., Ueffing M.;
RT   "The Parkinson disease causing LRRK2 mutation I2020T is associated
RT   with increased kinase activity.";
RL   Hum. Mol. Genet. 15:223-232(2006).
RN   [6]
RP   DISEASE.
RX   PubMed=16087219; DOI=10.1016/j.mad.2005.06.010;
RA   Toft M., Sando S.B., Melquist S., Ross O.A., White L.R., Aasly J.O.,
RA   Farrer M.J.;
RT   "LRRK2 mutations are not common in Alzheimer's disease.";
RL   Mech. Ageing Dev. 126:1201-1205(2005).
RN   [7]
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS PARK8 CYS-1441
RP   AND SER-2019.
RX   PubMed=16269541; DOI=10.1073/pnas.0507360102;
RA   West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A.,
RA   Dawson V.L., Dawson T.M.;
RT   "Parkinson's disease-associated mutations in leucine-rich repeat
RT   kinase 2 augment kinase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:16842-16847(2005).
RN   [8]
RP   SUBCELLULAR LOCATION, INTERACTION WITH PARK2, AND POSSIBLE FUNCTION.
RX   PubMed=16352719; DOI=10.1073/pnas.0508052102;
RA   Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B.,
RA   Dawson V.L., Dawson T.M., Ross C.A.;
RT   "Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin and mutant
RT   LRRK2 induces neuronal degeneration.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:18676-18681(2005).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=16532471; DOI=10.1002/ana.20808;
RA   Galter D., Westerlund M., Carmine A., Lindqvist E., Sydow O.,
RA   Olson L.;
RT   "LRRK2 expression linked to dopamine-innervated areas.";
RL   Ann. Neurol. 59:714-719(2006).
RN   [10]
RP   VARIANTS PARK8 GLY-1441 AND CYS-1699, AND TISSUE SPECIFICITY.
RX   PubMed=15541308; DOI=10.1016/j.neuron.2004.10.023;
RA   Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J.,
RA   van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N.L.,
RA   Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S.,
RA   de Silva R., Lees A.J., Marti-Masso J.F., Perez-Tur J., Wood N.W.,
RA   Singleton A.B.;
RT   "Cloning of the gene containing mutations that cause PARK8-linked
RT   Parkinson's disease.";
RL   Neuron 44:595-600(2004).
RN   [11]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15726496; DOI=10.1086/429256;
RA   Kachergus J.M., Mata I.F., Hulihan M., Taylor J.P., Lincoln S.,
RA   Aasly J.O., Gibson J.M., Ross O.A., Lynch T., Wiley J., Payami H.,
RA   Nutt J., Maraganore D.M., Czyzewski K., Styczynska M., Wszolek Z.K.,
RA   Farrer M.J., Toft M.;
RT   "Identification of a novel LRRK2 mutation linked to autosomal dominant
RT   parkinsonism: evidence of a common founder across European
RT   populations.";
RL   Am. J. Hum. Genet. 76:672-680(2005).
RN   [12]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15732108; DOI=10.1002/ana.20401;
RA   Hernandez D.G., Paisan-Ruiz C., McInerney-Leo A., Jain S.,
RA   Meyer-Lindenberg A., Evans E.W., Berman K.F., Johnson J., Auburger G.,
RA   Schaeffer A.A., Lopez G.J., Nussbaum R.L., Singleton A.B.;
RT   "Clinical and positron emission tomography of Parkinson's disease
RT   caused by LRRK2.";
RL   Ann. Neurol. 57:453-456(2005).
RN   [13]
RP   VARIANT PARK8/PD SER-2019.
RX   PubMed=15852371; DOI=10.1002/ana.20456;
RA   Aasly J.O., Toft M., Fernandez-Mata I., Kachergus J.M., Hulihan M.,
RA   White L.R., Farrer M.J.;
RT   "Clinical features of LRRK2-associated Parkinson's disease in central
RT   Norway.";
RL   Ann. Neurol. 57:762-765(2005).
RN   [14]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=16240353; DOI=10.1002/ana.20636;
RG   French Parkinson's disease genetics study group;
RA   Lesage S., Ibanez P., Lohmann E., Pollak P., Tison F., Tazir M.,
RA   Leutenegger A.-L., Guimaraes J., Bonnet A.-M., Agid Y., Duerr A.,
RA   Brice A.;
RT   "G2019S LRRK2 mutation in French and North African families with
RT   Parkinson's disease.";
RL   Ann. Neurol. 58:784-787(2005).
RN   [15]
RP   VARIANT PARK8 THR-2020.
RX   PubMed=15880653; DOI=10.1002/ana.20484;
RA   Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H.,
RA   Tsuji S., Obata F.;
RT   "An LRRK2 mutation as a cause for the parkinsonism in the original
RT   PARK8 family.";
RL   Ann. Neurol. 57:918-921(2005).
RN   [16]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15929036; DOI=10.1002/ana.20510;
RA   Deng H., Le W., Guo Y., Hunter C.B., Xie W., Jankovic J.;
RT   "Genetic and clinical identification of Parkinson's disease patients
RT   with LRRK2 G2019S mutation.";
RL   Ann. Neurol. 57:933-934(2005).
RN   [17]
RP   VARIANTS PARK8 MET-793; ARG-930; CYS-1096 THR-1228; SER-2019 AND
RP   THR-2020, AND VARIANT LYS-551.
RX   PubMed=16251215; DOI=10.1093/brain/awh666;
RA   Berg D., Schweitzer K., Leitner P., Zimprich A., Lichtner P.,
RA   Belcredi P., Bruessel T., Schulte C., Maass S., Naegele T.;
RT   "Type and frequency of mutations in the LRRK2 gene in familial and
RT   sporadic Parkinson's disease.";
RL   Brain 128:3000-3011(2005).
RN   [18]
RP   VARIANTS PARK8 CYS-1699; HIS-1941; SER-2019 AND ILE-2356.
RX   PubMed=16272164; DOI=10.1093/brain/awh667;
RA   Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P.M.,
RA   Holton J.L., Healy D.G., Gilks W.P., Sweeney M.G., Ganguly M.,
RA   Gibbons V., Gandhi S., Vaughan J., Eunson L.H., Katzenschlager R.,
RA   Gayton J., Lennox G., Revesz T., Nicholl D., Bhatia K.P., Quinn N.,
RA   Brooks D., Lees A.J., Davis M.B., Piccini P., Singleton A.B.,
RA   Wood N.W.;
RT   "Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial
RT   Parkinson's disease: clinical, pathological, olfactory and functional
RT   imaging and genetic data.";
RL   Brain 128:2786-2796(2005).
RN   [19]
RP   VARIANTS PARK8 VAL-1371; CYS-1441 AND SER-2019.
RX   PubMed=16333314; DOI=10.1038/sj.ejhg.5201539;
RA   Di Fonzo A., Tassorelli C., De Mari M., Chien H.F., Ferreira J.,
RA   Rohe C.F., Riboldazzi G., Antonini A., Albani G., Mauro A.,
RA   Marconi R., Abbruzzese G., Lopiano L., Fincati E., Guidi M.,
RA   Marini P., Stocchi F., Onofrj M., Toni V., Tinazzi M., Fabbrini G.,
RA   Lamberti P., Vanacore N., Meco G., Leitner P., Uitti R.J.,
RA   Wszolek Z.K., Gasser T., Simons E.J., Breedveld G.J., Goldwurm S.,
RA   Pezzoli G., Sampaio C., Barbosa E., Martignoni E., Oostra B.A.,
RA   Bonifati V.;
RT   "Comprehensive analysis of the LRRK2 gene in sixty families with
RT   Parkinson's disease.";
RL   Eur. J. Hum. Genet. 14:322-331(2006).
RN   [20]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=16272257; DOI=10.1136/jmg.2005.035568;
RA   Goldwurm S., Di Fonzo A., Simons E.J., Rohe C.F., Zini M., Canesi M.,
RA   Tesei S., Zecchinelli A., Antonini A., Mariani C., Meucci N.,
RA   Sacilotto G., Sironi F., Salani G., Ferreira J., Chien H.F.,
RA   Fabrizio E., Vanacore N., Dalla Libera A., Stocchi F., Diroma C.,
RA   Lamberti P., Sampaio C., Meco G., Barbosa E., Bertoli-Avella A.M.,
RA   Breedveld G.J., Oostra B.A., Pezzoli G., Bonifati V.;
RT   "The G6055A (G2019S) mutation in LRRK2 is frequent in both early and
RT   late onset Parkinson's disease and originates from a common
RT   ancestor.";
RL   J. Med. Genet. 42:E65-E65(2005).
RN   [21]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15680455; DOI=10.1016/S0140-6736(05)17828-3;
RG   The Parkinson study group-PROGENI investigators;
RA   Nichols W.C., Pankratz N., Hernandez D., Paisan-Ruiz C., Jain S.,
RA   Halter C.A., Michaels V.E., Reed T., Rudolph A., Shults C.W.,
RA   Singleton A., Foroud T.;
RT   "Genetic screening for a single common LRRK2 mutation in familial
RT   Parkinson's disease.";
RL   Lancet 365:410-412(2005).
RN   [22]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15680456; DOI=10.1016/S0140-6736(05)17829-5;
RG   The Italian Parkinson genetics network;
RA   Di Fonzo A., Rohe C.F., Ferreira J., Chien H.F., Vacca L., Stocchi F.,
RA   Guedes L., Fabrizio E., Manfredi M., Vanacore N., Goldwurm S.,
RA   Breedveld G.J., Sampaio C., Meco G., Barbosa E., Oostra B.A.,
RA   Bonifati V.;
RT   "A frequent LRRK2 gene mutation associated with autosomal dominant
RT   Parkinson's disease.";
RL   Lancet 365:412-415(2005).
RN   [23]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15680457; DOI=10.1016/S0140-6736(05)17830-1;
RA   Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A.,
RA   Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., Lynch J.M.,
RA   Healy D.G., Holton J.L., Revesz T., Wood N.W.;
RT   "A common LRRK2 mutation in idiopathic Parkinson's disease.";
RL   Lancet 365:415-416(2005).
RN   [24]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15811454; DOI=10.1016/S0140-6736(05)74809-1;
RA   Toft M., Mata I.F., Kachergus J.M., Ross O.A., Farrer M.J.;
RT   "LRRK2 mutations and Parkinsonism.";
RL   Lancet 365:1229-1230(2005).
RN   [25]
RP   VARIANT SER-2019.
RX   PubMed=16001413; DOI=10.1002/mds.20618;
RA   Kay D.M., Kramer P., Higgins D.S., Zabetian C.P., Payami H.;
RT   "Escaping Parkinson's disease: a neurologically healthy octogenarian
RT   with the LRRK2 G2019S mutation.";
RL   Mov. Disord. 20:1077-1078(2005).
RN   [26]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=16250030; DOI=10.1002/mds.20751;
RA   Kay D.M., Zabetian C.P., Factor S.A., Nutt J.G., Samii A.,
RA   Griffith A., Bird T.D., Kramer P., Higgins D.S., Payami H.;
RT   "Parkinson's disease and LRRK2: frequency of a common mutation in U.S.
RT   movement disorder clinics.";
RL   Mov. Disord. 21:519-523(2006).
RN   [27]
RP   VARIANTS PARK8 CYS-1441; GLY-1441; HIS-1441; GLN-1514; SER-1542;
RP   GLU-1598; CYS-1699; THR-1869; THR-2012; SER-2019; THR-2020 AND
RP   ARG-2385, AND VARIANTS PRO-119; LYS-551; VAL-723; MET-793; VAL-1122;
RP   ALA-1262; HIS-1398; PRO-1628; THR-1646; THR-1647; ASP-2081; LEU-2119;
RP   ILE-2261 AND THR-2397.
RX   PubMed=16172858; DOI=10.1007/s10048-005-0005-1;
RA   Mata I.F., Kachergus J.M., Taylor J.P., Lincoln S., Aasly J.,
RA   Lynch T., Hulihan M.M., Cobb S.A., Wu R.-M., Lu C.-S., Lahoz C.,
RA   Wszolek Z.K., Farrer M.J.;
RT   "Lrrk2 pathogenic substitutions in Parkinson's disease.";
RL   Neurogenetics 6:171-177(2005).
RN   [28]
RP   VARIANTS PARK8 VAL-1371 AND SER-2019, AND VARIANTS HIS-1398 AND
RP   THR-2397.
RX   PubMed=16157901; DOI=10.1212/01.WNL.0000167552.79769.b3;
RA   Paisan-Ruiz C., Lang A.E., Kawarai T., Sato C., Salehi-Rad S.,
RA   Fisman G.K., Al-Khairallah T., St George-Hyslop P.H., Singleton A.,
RA   Rogaeva E.;
RT   "LRRK2 gene in Parkinson disease: mutation analysis and case control
RT   association study.";
RL   Neurology 65:696-700(2005).
RN   [29]
RP   VARIANT PARK8 GLN-1067.
RX   PubMed=16247070; DOI=10.1212/01.wnl.0000180517.70572.37;
RA   Skipper L., Shen H., Chua E., Bonnard C., Kolatkar P., Tan L.C.S.,
RA   Jamora R.D., Puvan K., Puong K.Y., Zhao Y., Pavanni R., Wong M.C.,
RA   Yuen Y., Farrer M., Liu J.J., Tan E.K.;
RT   "Analysis of LRRK2 functional domains in nondominant Parkinson
RT   disease.";
RL   Neurology 65:1319-1321(2005).
RN   [30]
RP   VARIANTS PARK8 MET-793; THR-1869 AND SER-2019.
RX   PubMed=16157908; DOI=10.1212/01.WNL.0000169023.51764.b0;
RA   Farrer M., Stone J., Mata I.F., Lincoln S., Kachergus J., Hulihan M.,
RA   Strain K.J., Maraganore D.M.;
RT   "LRRK2 mutations in Parkinson disease.";
RL   Neurology 65:738-740(2005).
RN   [31]
RP   VARIANTS PARK8 CYS-1441; HIS-1441 AND SER-2019.
RX   PubMed=16157909; DOI=10.1212/01.WNL.0000172630.22804.73;
RA   Zabetian C.P., Samii A., Mosley A.D., Roberts J.W., Leis B.C.,
RA   Yearout D., Raskind W.H., Griffith A.;
RT   "A clinic-based study of the LRRK2 gene in Parkinson disease yields
RT   new mutations.";
RL   Neurology 65:741-744(2005).
RN   [32]
RP   VARIANT PARK8 GLY-1441.
RX   PubMed=15925109; DOI=10.1016/j.neulet.2005.03.033;
RA   Mata I.F., Taylor J.P., Kachergus J., Hulihan M., Huerta C., Lahoz C.,
RA   Blazquez M., Guisasola L.M., Salvador C., Ribacoba R., Martinez C.,
RA   Farrer M., Alvarez V.;
RT   "LRRK2 R1441G in Spanish patients with Parkinson's disease.";
RL   Neurosci. Lett. 382:309-311(2005).
RN   [33]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=16298482; DOI=10.1016/j.neulet.2005.10.083;
RA   Infante J., Rodriguez E., Combarros O., Mateo I., Fontalba A.,
RA   Pascual J., Oterino A., Polo J.M., Leno C., Berciano J.;
RT   "LRRK2 G2019S is a common mutation in Spanish patients with late-onset
RT   Parkinson's disease.";
RL   Neurosci. Lett. 395:224-226(2006).
RN   [34]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=16102999; DOI=10.1016/j.parkreldis.2005.05.004;
RA   Gosal D., Ross O.A., Wiley J., Irvine G.B., Johnston J.A., Toft M.,
RA   Mata I.F., Kachergus J., Hulihan M., Taylor J.P., Lincoln S.J.,
RA   Farrer M.J., Lynch T., Mark Gibson J.;
RT   "Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a
RT   link between familial and idiopathic PD.";
RL   Parkinsonism Relat. Disord. 11:349-352(2005).
RN   [35]
RP   VARIANTS PARK8 CYS-1441; GLY-1441 AND SER-2019.
RX   PubMed=16533964; DOI=10.1001/archneur.63.3.377;
RA   Gaig C., Ezquerra M., Marti M.J., Munoz E., Valldeoriola F.,
RA   Tolosa E.;
RT   "LRRK2 mutations in Spanish patients with Parkinson disease:
RT   frequency, clinical features, and incomplete penetrance.";
RL   Arch. Neurol. 63:377-382(2006).
RN   [36]
RP   CHARACTERIZATION OF VARIANT ARG-2385, AND ASSOCIATION WITH PARKINSON
RP   DISEASE.
RX   PubMed=17019612; DOI=10.1007/s00439-006-0268-0;
RA   Tan E.K., Zhao Y., Skipper L., Tan M.G., Di Fonzo A., Sun L.,
RA   Fook-Chong S., Tang S., Chua E., Yuen Y., Tan L., Pavanni R.,
RA   Wong M.C., Kolatkar P., Lu C.S., Bonifati V., Liu J.J.;
RT   "The LRRK2 Gly2385Arg variant is associated with Parkinson's disease:
RT   genetic and functional evidence.";
RL   Hum. Genet. 120:857-863(2007).
RN   [37]
RP   VARIANTS [LARGE SCALE ANALYSIS] PRO-119; VAL-419; LYS-551; VAL-723;
RP   HIS-1398; GLN-1514; SER-1542; GLN-1550 AND PRO-1723.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [38]
RP   VARIANTS PARK8 VAL-712; LEU-1728; HIS-1728; SER-2019; MET-2141;
RP   HIS-2143 AND HIS-2466, AND VARIANTS SER-228; VAL-716; GLU-871;
RP   PHE-1870 AND LYS-2395.
RX   PubMed=18213618; DOI=10.1002/humu.20668;
RA   Paisan-Ruiz C., Nath P., Washecka N., Gibbs J.R., Singleton A.B.;
RT   "Comprehensive analysis of LRRK2 in publicly available Parkinson's
RT   disease cases and neurologically normal controls.";
RL   Hum. Mutat. 29:485-490(2008).
CC   -!- FUNCTION: Probable protein kinase whose role is not yet known. May
CC       play a role in the phosphorylation of proteins central to
CC       Parkinson disease. May also have GTPase activity.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts with PARK2.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Membrane; Peripheral membrane
CC       protein. Note=Localized in the cytoplasm and associated with
CC       cellular membrane structures. Associates with the mitochondrial
CC       outer membrane.
CC   -!- TISSUE SPECIFICITY: Expressed throughout the adult brain, but at a
CC       lower level than in heart and liver. Also expressed in placenta,
CC       lung, skeletal muscle, kidney and pancreas. In the brain,
CC       expressed in the cerebellum, cerebral cortex, medulla, spinal cord
CC       occipital pole, frontal lobe, temporal lobe and putamen.
CC       Expression is particularly high in brain dopaminoceptive areas.
CC   -!- DISEASE: Defects in LRRK2 are the cause of Parkinson disease type
CC       8 (PARK8) [MIM:607060]. A slowly progressive neurodegenerative
CC       disorder characterized by bradykinesia, rigidity, resting tremor,
CC       postural instability, neuronal loss in the substantia nigra, and
CC       the presence of neurofibrillary MAPT (tau)-positive and Lewy
CC       bodies in some patients.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family.
CC   -!- SIMILARITY: Contains 16 LRR (leucine-rich) repeats.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 Roc domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/LRRK2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY792511; AAV63975.1; -; mRNA.
DR   EMBL; AC079630; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC084290; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107023; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL834529; CAD39185.1; -; mRNA.
DR   IPI; IPI00175649; -.
DR   RefSeq; NP_940980.3; -.
DR   UniGene; Hs.187636; -.
DR   PDB; 2ZEJ; X-ray; 2.00 A; A/B=1333-1516.
DR   PDB; 3D6T; X-ray; 2.43 A; B=1336-1505.
DR   PDBsum; 2ZEJ; -.
DR   PDBsum; 3D6T; -.
DR   ProteinModelPortal; Q5S007; -.
DR   SMR; Q5S007; 557-584, 1336-1638, 1546-1856, 1870-2134.
DR   DIP; DIP-29684N; -.
DR   STRING; Q5S007; -.
DR   PhosphoSite; Q5S007; -.
DR   PRIDE; Q5S007; -.
DR   Ensembl; ENST00000298910; ENSP00000298910; ENSG00000188906.
DR   GeneID; 120892; -.
DR   KEGG; hsa:120892; -.
DR   CTD; 120892; -.
DR   GeneCards; GC12P040590; -.
DR   H-InvDB; HIX0010547; -.
DR   HGNC; HGNC:18618; LRRK2.
DR   HPA; HPA014293; -.
DR   MIM; 168600; phenotype.
DR   MIM; 607060; phenotype.
DR   MIM; 609007; gene.
DR   Orphanet; 2828; Genetic Parkinson disease.
DR   PharmGKB; PA134968052; -.
DR   HOGENOM; HBG445818; -.
DR   HOVERGEN; HBG081937; -.
DR   InParanoid; Q5S007; -.
DR   OMA; VMLSMLM; -.
DR   BRENDA; 2.7.11.1; 247.
DR   NextBio; 80641; -.
DR   ArrayExpress; Q5S007; -.
DR   Bgee; Q5S007; -.
DR   CleanEx; HS_LRRK2; -.
DR   Genevestigator; Q5S007; -.
DR   GermOnline; ENSG00000188906; Homo sapiens.
DR   GO; GO:0032473; C:external side of mitochondrial outer membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0034211; F:GTP-dependent protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0005096; F:GTPase activator activity; IDA:UniProtKB.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:BHF-UCL.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:BHF-UCL.
DR   GO; GO:0070997; P:neuron death; IMP:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; IDA:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0040012; P:regulation of locomotion; IMP:BHF-UCL.
DR   GO; GO:0006979; P:response to oxidative stress; IMP:BHF-UCL.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IEA:InterPro.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR013684; MIRO-like.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001806; Ras_GTPase.
DR   InterPro; IPR020859; ROC_GTPase.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR005225; Small_GTP-bd.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR011046; WD40_repeat-like_dom.
DR   Gene3D; G3DSA:1.25.40.20; ANK; 1.
DR   Gene3D; G3DSA:1.25.10.10; ARM-like; 3.
DR   Gene3D; G3DSA:2.130.10.10; WD40/YVTN_repeat-like; 2.
DR   Pfam; PF00560; LRR_1; 3.
DR   Pfam; PF08477; Miro; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR00449; RASTRNSFRMNG.
DR   SMART; SM00369; LRR_TYP; 1.
DR   SMART; SM00320; WD40; 1.
DR   SUPFAM; SSF48371; ARM-type_fold; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF50978; WD40_like; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51450; LRR; 11.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS51424; ROC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Coiled coil; Complete proteome; Cytoplasm;
KW   Disease mutation; GTP-binding; GTPase activation; Kinase;
KW   Leucine-rich repeat; Membrane; Neurodegeneration; Nucleotide-binding;
KW   Parkinson disease; Polymorphism; Repeat;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1   2527       Leucine-rich repeat serine/threonine-
FT                                protein kinase 2.
FT                                /FTId=PRO_0000086238.
FT   REPEAT      226    249       LRR 1.
FT   REPEAT      791    815       LRR 2.
FT   REPEAT      981   1004       LRR 3.
FT   REPEAT     1010   1033       LRR 4.
FT   REPEAT     1035   1057       LRR 5.
FT   REPEAT     1059   1081       LRR 6.
FT   REPEAT     1082   1105       LRR 7.
FT   REPEAT     1107   1127       LRR 8.
FT   REPEAT     1128   1151       LRR 9.
FT   REPEAT     1172   1194       LRR 10.
FT   REPEAT     1195   1219       LRR 11.
FT   REPEAT     1221   1243       LRR 12.
FT   REPEAT     1244   1268       LRR 13.
FT   REPEAT     1270   1291       LRR 14.
FT   DOMAIN     1328   1511       Roc.
FT   REPEAT     1556   1579       LRR 15.
FT   REPEAT     1861   1887       LRR 16.
FT   DOMAIN     1879   2138       Protein kinase.
FT   NP_BIND    1341   1348       GTP (Potential).
FT   NP_BIND    1885   1893       ATP (By similarity).
FT   NP_BIND    2098   2121       GTP (Potential).
FT   NP_BIND    2295   2298       GTP (Potential).
FT   COILED      319    348       Potential.
FT   COMPBIAS    728    731       Poly-Leu.
FT   ACT_SITE   1994   1994       Proton acceptor (By similarity).
FT   BINDING    1906   1906       ATP (By similarity).
FT   VARIANT      50     50       R -> H (in dbSNP:rs2256408).
FT                                /FTId=VAR_024931.
FT   VARIANT     119    119       L -> P (in dbSNP:rs33995463).
FT                                /FTId=VAR_024932.
FT   VARIANT     228    228       C -> S (in dbSNP:rs56108242).
FT                                /FTId=VAR_054740.
FT   VARIANT     419    419       A -> V (in dbSNP:rs34594498).
FT                                /FTId=VAR_033903.
FT   VARIANT     551    551       N -> K (in dbSNP:rs7308720).
FT                                /FTId=VAR_024933.
FT   VARIANT     712    712       M -> V (in PARK8).
FT                                /FTId=VAR_054741.
FT   VARIANT     716    716       A -> V.
FT                                /FTId=VAR_054742.
FT   VARIANT     723    723       I -> V (in dbSNP:rs10878307).
FT                                /FTId=VAR_024934.
FT   VARIANT     755    755       P -> L (in dbSNP:rs34410987).
FT                                /FTId=VAR_033904.
FT   VARIANT     793    793       R -> M (in PARK8; could be a
FT                                polymorphism; dbSNP:rs35173587).
FT                                /FTId=VAR_024935.
FT   VARIANT     871    871       K -> E.
FT                                /FTId=VAR_054743.
FT   VARIANT     930    930       Q -> R (in PARK8; could be a
FT                                poymorphism).
FT                                /FTId=VAR_024936.
FT   VARIANT     944    944       D -> Y (in dbSNP:rs17519916).
FT                                /FTId=VAR_024937.
FT   VARIANT    1067   1067       R -> Q (in PARK8).
FT                                /FTId=VAR_024938.
FT   VARIANT    1096   1096       S -> C (in PARK8; could be a
FT                                polymorphism).
FT                                /FTId=VAR_024939.
FT   VARIANT    1122   1122       I -> V (in PARK8; dbSNP:rs34805604).
FT                                /FTId=VAR_024940.
FT   VARIANT    1228   1228       S -> T (in PARK8).
FT                                /FTId=VAR_024941.
FT   VARIANT    1262   1262       P -> A (in dbSNP:rs4640000).
FT                                /FTId=VAR_024942.
FT   VARIANT    1371   1371       I -> V (in PARK8; could be a
FT                                polymorphism; dbSNP:rs17466213).
FT                                /FTId=VAR_024943.
FT   VARIANT    1375   1375       D -> E (in dbSNP:rs28365226).
FT                                /FTId=VAR_047022.
FT   VARIANT    1398   1398       R -> H (in dbSNP:rs7133914).
FT                                /FTId=VAR_024944.
FT   VARIANT    1441   1441       R -> C (in PARK; shows an increase in
FT                                activity in both autophosphorylation and
FT                                phosphorylation of a generic substrate).
FT                                /FTId=VAR_024945.
FT   VARIANT    1441   1441       R -> G (in PARK8; dbSNP:rs33939927).
FT                                /FTId=VAR_024946.
FT   VARIANT    1441   1441       R -> H (in PARK8; pathogenicity has yet
FT                                to be confirmed; dbSNP:rs34995376).
FT                                /FTId=VAR_024947.
FT   VARIANT    1514   1514       R -> Q (in PARK8; pathogenicity has yet
FT                                to be confirmed; might have an effect on
FT                                protein structure; dbSNP:rs35507033).
FT                                /FTId=VAR_024948.
FT   VARIANT    1542   1542       P -> S (in PARK8; pathogenicity has yet
FT                                to be confirmed; might have an effect on
FT                                protein structure; dbSNP:rs33958906).
FT                                /FTId=VAR_024949.
FT   VARIANT    1550   1550       R -> Q (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040678.
FT   VARIANT    1598   1598       V -> E (in PARK8; pathogenicity has yet
FT                                to be confirmed; might have an effect on
FT                                protein structure; dbSNP:rs721710).
FT                                /FTId=VAR_024950.
FT   VARIANT    1628   1628       R -> P (in dbSNP:rs33949390).
FT                                /FTId=VAR_024951.
FT   VARIANT    1646   1646       M -> T (in dbSNP:rs35303786).
FT                                /FTId=VAR_024952.
FT   VARIANT    1647   1647       S -> T (in dbSNP:rs11564148).
FT                                /FTId=VAR_024953.
FT   VARIANT    1699   1699       Y -> C (in PARK8; dbSNP:rs35801418).
FT                                /FTId=VAR_024954.
FT   VARIANT    1723   1723       R -> P (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_040679.
FT   VARIANT    1728   1728       R -> H (in PARK8).
FT                                /FTId=VAR_054744.
FT   VARIANT    1728   1728       R -> L (in PARK8).
FT                                /FTId=VAR_054745.
FT   VARIANT    1869   1869       M -> T (in PARK8; pathogenicity has yet
FT                                to be confirmed; dbSNP:rs35602796).
FT                                /FTId=VAR_024955.
FT   VARIANT    1870   1870       L -> F.
FT                                /FTId=VAR_054746.
FT   VARIANT    1941   1941       R -> H (in PARK8).
FT                                /FTId=VAR_024956.
FT   VARIANT    2012   2012       I -> T (in PARK8; pathogenicity
FT                                uncertain; dbSNP:rs34015634).
FT                                /FTId=VAR_024957.
FT   VARIANT    2019   2019       G -> S (in PARK8; shows an increase in
FT                                activity in both autophosphorylation and
FT                                phosphorylation of a generic substrate;
FT                                dbSNP:rs34637584).
FT                                /FTId=VAR_024958.
FT   VARIANT    2020   2020       I -> T (in PARK8; significant increase in
FT                                autophosphorylation of about 40% in
FT                                comparison to wild-type protein in vitro;
FT                                dbSNP:rs35870237).
FT                                /FTId=VAR_024959.
FT   VARIANT    2081   2081       N -> D (in dbSNP:rs33995883).
FT                                /FTId=VAR_024960.
FT   VARIANT    2119   2119       P -> L (in dbSNP:rs12423862).
FT                                /FTId=VAR_024961.
FT   VARIANT    2141   2141       T -> M (in PARK8).
FT                                /FTId=VAR_054747.
FT   VARIANT    2143   2143       R -> H (in PARK8).
FT                                /FTId=VAR_054748.
FT   VARIANT    2261   2261       N -> I (in dbSNP:rs12581902).
FT                                /FTId=VAR_024962.
FT   VARIANT    2356   2356       T -> I (in PARK8).
FT                                /FTId=VAR_024963.
FT   VARIANT    2385   2385       G -> R (associated with Parkinson
FT                                disease; under conditions of oxidative
FT                                stress the variant protein is more toxic
FT                                and is associated with a higher rate of
FT                                apoptosis; dbSNP:rs34778348).
FT                                /FTId=VAR_024964.
FT   VARIANT    2395   2395       E -> K.
FT                                /FTId=VAR_054749.
FT   VARIANT    2397   2397       M -> T (in dbSNP:rs3761863).
FT                                /FTId=VAR_024965.
FT   VARIANT    2466   2466       L -> H (in PARK8).
FT                                /FTId=VAR_054750.
FT   CONFLICT    212    212       L -> S (in Ref. 1; AAV63975).
FT   STRAND     1336   1341
FT   HELIX      1347   1354
FT   STRAND     1370   1377
FT   STRAND     1389   1395
FT   HELIX      1398   1402
FT   HELIX      1406   1411
FT   STRAND     1412   1420
FT   HELIX      1421   1423
FT   HELIX      1425   1429
FT   HELIX      1431   1441
FT   STRAND     1446   1452
FT   HELIX      1454   1456
FT   HELIX      1459   1472
FT   TURN       1473   1475
FT   STRAND     1481   1487
FT   HELIX      1495   1509
SQ   SEQUENCE   2527 AA;  286103 MW;  26142A0CECBBC3F4 CRC64;
     MASGSCQGCE EDEETLKKLI VRLNNVQEGK QIETLVQILE DLLVFTYSER ASKLFQGKNI
     HVPLLIVLDS YMRVASVQQV GWSLLCKLIE VCPGTMQSLM GPQDVGNDWE VLGVHQLILK
     MLTVHNASVN LSVIGLKTLD LLLTSGKITL LILDEESDIF MLIFDAMHSF PANDEVQKLG
     CKALHVLFER VSEEQLTEFV ENKDYMILLS ALTNFKDEEE IVLHVLHCLH SLAIPCNNVE
     VLMSGNVRCY NIVVEAMKAF PMSERIQEVS CCLLHRLTLG NFFNILVLNE VHEFVVKAVQ
     QYPENAALQI SALSCLALLT ETIFLNQDLE EKNENQENDD EGEEDKLFWL EACYKALTWH
     RKNKHVQEAA CWALNNLLMY QNSLHEKIGD EDGHFPAHRE VMLSMLMHSS SKEVFQASAN
     ALSTLLEQNV NFRKILLSKG IHLNVLELMQ KHIHSPEVAE SGCKMLNHLF EGSNTSLDIM
     AAVVPKILTV MKRHETSLPV QLEALRAILH FIVPGMPEES REDTEFHHKL NMVKKQCFKN
     DIHKLVLAAL NRFIGNPGIQ KCGLKVISSI VHFPDALEML SLEGAMDSVL HTLQMYPDDQ
     EIQCLGLSLI GYLITKKNVF IGTGHLLAKI LVSSLYRFKD VAEIQTKGFQ TILAILKLSA
     SFSKLLVHHS FDLVIFHQMS SNIMEQKDQQ FLNLCCKCFA KVAMDDYLKN VMLERACDQN
     NSIMVECLLL LGADANQAKE GSSLICQVCE KESSPKLVEL LLNSGSREQD VRKALTISIG
     KGDSQIISLL LRRLALDVAN NSICLGGFCI GKVEPSWLGP LFPDKTSNLR KQTNIASTLA
     RMVIRYQMKS AVEEGTASGS DGNFSEDVLS KFDEWTFIPD SSMDSVFAQS DDLDSEGSEG
     SFLVKKKSNS ISVGEFYRDA VLQRCSPNLQ RHSNSLGPIF DHEDLLKRKR KILSSDDSLR
     SSKLQSHMRH SDSISSLASE REYITSLDLS ANELRDIDAL SQKCCISVHL EHLEKLELHQ
     NALTSFPQQL CETLKSLTHL DLHSNKFTSF PSYLLKMSCI ANLDVSRNDI GPSVVLDPTV
     KCPTLKQFNL SYNQLSFVPE NLTDVVEKLE QLILEGNKIS GICSPLRLKE LKILNLSKNH
     ISSLSENFLE ACPKVESFSA RMNFLAAMPF LPPSMTILKL SQNKFSCIPE AILNLPHLRS
     LDMSSNDIQY LPGPAHWKSL NLRELLFSHN QISILDLSEK AYLWSRVEKL HLSHNKLKEI
     PPEIGCLENL TSLDVSYNLE LRSFPNEMGK LSKIWDLPLD ELHLNFDFKH IGCKAKDIIR
     FLQQRLKKAV PYNRMKLMIV GNTGSGKTTL LQQLMKTKKS DLGMQSATVG IDVKDWPIQI
     RDKRKRDLVL NVWDFAGREE FYSTHPHFMT QRALYLAVYD LSKGQAEVDA MKPWLFNIKA
     RASSSPVILV GTHLDVSDEK QRKACMSKIT KELLNKRGFP AIRDYHFVNA TEESDALAKL
     RKTIINESLN FKIRDQLVVG QLIPDCYVEL EKIILSERKN VPIEFPVIDR KRLLQLVREN
     QLQLDENELP HAVHFLNESG VLLHFQDPAL QLSDLYFVEP KWLCKIMAQI LTVKVEGCPK
     HPKGIISRRD VEKFLSKKRK FPKNYMSQYF KLLEKFQIAL PIGEEYLLVP SSLSDHRPVI
     ELPHCENSEI IIRLYEMPYF PMGFWSRLIN RLLEISPYML SGRERALRPN RMYWRQGIYL
     NWSPEAYCLV GSEVLDNHPE SFLKITVPSC RKGCILLGQV VDHIDSLMEE WFPGLLEIDI
     CGEGETLLKK WALYSFNDGE EHQKILLDDL MKKAEEGDLL VNPDQPRLTI PISQIAPDLI
     LADLPRNIML NNDELEFEQA PEFLLGDGSF GSVYRAAYEG EEVAVKIFNK HTSLRLLRQE
     LVVLCHLHHP SLISLLAAGI RPRMLVMELA SKGSLDRLLQ QDKASLTRTL QHRIALHVAD
     GLRYLHSAMI IYRDLKPHNV LLFTLYPNAA IIAKIADYGI AQYCCRMGIK TSEGTPGFRA
     PEVARGNVIY NQQADVYSFG LLLYDILTTG GRIVEGLKFP NEFDELEIQG KLPDPVKEYG
     CAPWPMVEKL IKQCLKENPQ ERPTSAQVFD ILNSAELVCL TRRILLPKNV IVECMVATHH
     NSRNASIWLG CGHTDRGQLS FLDLNTEGYT SEEVADSRIL CLALVHLPVE KESWIVSGTQ
     SGTLLVINTE DGKKRHTLEK MTDSVTCLYC NSFSKQSKQK NFLLVGTADG KLAIFEDKTV
     KLKGAAPLKI LNIGNVSTPL MCLSESTNST ERNVMWGGCG TKIFSFSNDF TIQKLIETRT
     SQLFSYAAFS DSNIITVVVD TALYIAKQNS PVVEVWDKKT EKLCGLIDCV HFLREVMVKE
     NKESKHKMSY SGRVKTLCLQ KNTALWIGTG GGHILLLDLS TRRLIRVIYN FCNSVRVMMT
     AQLGSLKNVM LVLGYNRKNT EGTQKQKEIQ SCLTVWDINL PHEVQNLEKH IEVRKELAEK
     MRRTSVE
//
